BRPI0620806B8 - complexo e composição compreendendo um peptídeo e uma molécula carga, e uso da referida composição - Google Patents

complexo e composição compreendendo um peptídeo e uma molécula carga, e uso da referida composição

Info

Publication number
BRPI0620806B8
BRPI0620806B8 BRPI0620806A BRPI0620806A BRPI0620806B8 BR PI0620806 B8 BRPI0620806 B8 BR PI0620806B8 BR PI0620806 A BRPI0620806 A BR PI0620806A BR PI0620806 A BRPI0620806 A BR PI0620806A BR PI0620806 B8 BRPI0620806 B8 BR PI0620806B8
Authority
BR
Brazil
Prior art keywords
composition
peptide
complex
charge molecule
lactoferrin protein
Prior art date
Application number
BRPI0620806A
Other languages
English (en)
Portuguese (pt)
Inventor
Brock Roland
Fischer Rainer
Fotin-Mleczek Mariola
Hufnagel Hansjörg
Windhab Norbert
Original Assignee
Evonik Roehm Gmbh
Roehm Gmbh
Evonik Degussa Gmbh
Evonik Operations Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh, Roehm Gmbh, Evonik Degussa Gmbh, Evonik Operations Gmbh filed Critical Evonik Roehm Gmbh
Publication of BRPI0620806A2 publication Critical patent/BRPI0620806A2/pt
Publication of BRPI0620806B1 publication Critical patent/BRPI0620806B1/pt
Publication of BRPI0620806B8 publication Critical patent/BRPI0620806B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0620806A 2005-12-30 2006-10-25 complexo e composição compreendendo um peptídeo e uma molécula carga, e uso da referida composição BRPI0620806B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05028755 2005-12-30
EP05028755.6 2005-12-30
PCT/EP2006/010271 WO2007076904A1 (en) 2005-12-30 2006-10-25 Peptides useful as cell-penetrating peptides

Publications (3)

Publication Number Publication Date
BRPI0620806A2 BRPI0620806A2 (pt) 2011-11-22
BRPI0620806B1 BRPI0620806B1 (pt) 2017-12-05
BRPI0620806B8 true BRPI0620806B8 (pt) 2022-07-05

Family

ID=37491778

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0620806A BRPI0620806B8 (pt) 2005-12-30 2006-10-25 complexo e composição compreendendo um peptídeo e uma molécula carga, e uso da referida composição

Country Status (16)

Country Link
US (3) US20100061932A1 (https=)
EP (1) EP1966240B3 (https=)
JP (1) JP5264502B2 (https=)
KR (1) KR101317100B1 (https=)
CN (1) CN101395180B (https=)
AT (1) ATE501169T1 (https=)
AU (1) AU2006332193B2 (https=)
BR (1) BRPI0620806B8 (https=)
CA (1) CA2646833C (https=)
DE (1) DE602006020617D1 (https=)
ES (1) ES2361621T7 (https=)
IL (1) IL192131A (https=)
MX (1) MX2008008548A (https=)
PL (1) PL1966240T6 (https=)
SI (1) SI1966240T1 (https=)
WO (1) WO2007076904A1 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005051366A1 (de) 2005-10-25 2007-04-26 Degussa Gmbh Drug Delivery Systeme
EP2050461A1 (en) * 2007-10-19 2009-04-22 PharmaSurgics in Sweden AB Peptides based on the sequence of human lactoferrin and their use
EP2090584A1 (en) * 2008-02-13 2009-08-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Identification of a novel cysteine-rich cell penetrating peptide
CA2716565C (en) * 2008-02-28 2017-09-12 Toray Industries, Inc. Pharmaceutical composition for transnasal administration
WO2011005540A1 (en) 2009-06-22 2011-01-13 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
JP5818319B2 (ja) * 2009-12-14 2015-11-18 国立大学法人北海道大学 脂質膜構造体に細胞透過能を付与および／または脂質膜構造体の細胞透過能を増強するペプチド、ならびにそれらペプチドと結合した脂質を構成脂質として含む、細胞透過能を有するまたは細胞透過能が増強された脂質膜構造体
WO2011084061A1 (en) 2010-01-08 2011-07-14 Universitair Medisch Centrum St. Radboud Cpp (cell penetrating peptide) and its uses
FR2955773B1 (fr) * 2010-02-01 2017-05-26 Commissariat Energie Atomique Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
MX348337B (es) * 2010-11-26 2017-06-07 Evonik Roehm Gmbh Peptido derivado de lactoferrina humana para usarse como agente de enmascaramiento de antigenos.
CN102174078A (zh) * 2011-01-10 2011-09-07 中国药科大学 肿瘤细胞选择性穿膜肽的应用
CN102091036A (zh) * 2011-01-10 2011-06-15 中国药科大学 一种含有抗肿瘤药物的复合脂质体及其制备方法和用途
CN102153629B (zh) * 2011-01-20 2013-07-24 华中科技大学 一种短肽及其应用
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
AU2012262488A1 (en) 2011-05-31 2014-01-16 Airware, Inc. Re-calibration of AB NDIR gas sensors
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
CN102988295B (zh) * 2011-09-09 2015-07-29 复旦大学 一种穿膜肽修饰的纳米粒及其制备方法
CN102993296A (zh) * 2011-09-14 2013-03-27 广州格拉姆生物科技有限公司 牛乳铁蛋白肽及其制备方法
US12083158B2 (en) 2011-10-07 2024-09-10 Morehouse School Of Medicine Antibacterial compositions, methods of making and use thereof
WO2013052058A1 (en) * 2011-10-07 2013-04-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
US8669226B2 (en) 2011-10-07 2014-03-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
DE102011055229A1 (de) 2011-11-10 2013-05-16 Evonik Degussa Gmbh Verfahren zur Bereitstellung von Regelleistung mit einem Energiespeicher unter Ausnutzung von Toleranzen bei der Bestimmung der Frequenzabweichung
DE102011055231A1 (de) * 2011-11-10 2013-05-16 Evonik Industries Ag Verfahren zur Bereitstellung von Regelleistung
EP3375457B1 (en) 2011-11-24 2020-06-24 Positec Power Tools (Suzhou) Co., Ltd Peptide sequence design and use thereof for peptide-mediated sirna delivery
CN103169982B (zh) * 2011-12-23 2015-05-20 中国科学院上海药物研究所 生物活性肽修饰的纳米银及其制备方法和用途
CN103382217B (zh) * 2012-12-11 2015-05-27 任发政 穿膜肽和药物组合物及其制备方法和应用
WO2015023649A2 (en) * 2013-08-12 2015-02-19 3M Innovative Properties Company Peptides for enhancing transdermal delivery
WO2015075747A1 (en) * 2013-11-19 2015-05-28 Council Of Scientific And Industrial Research Cell-penetrating peptide for biomolecule delivery
BR112016013516A8 (pt) 2013-12-12 2020-05-19 Life Technologies Corp complexo de transfecção e seu uso para aumentar transporte de molécula de carga em células e para o tratamento de câncer e terapia gênica, bem como método in vitro para fornecer um poliânion a uma célula
CN103784406A (zh) * 2014-01-20 2014-05-14 同济大学 一种偶联穿膜肽和mmp酶切位点的纳米颗粒
EP3148515B1 (en) * 2014-05-28 2019-12-04 Evonik Degussa GmbH Nanoparticle
CN107207627B (zh) * 2015-02-27 2022-05-24 学校法人常翔学园 具有膜透过性肽链的多糖衍生物
KR101647804B1 (ko) * 2015-06-24 2016-08-11 한국과학기술연구원 신규 세포투과 펩타이드 및 이의 용도
CN108456254B (zh) * 2017-02-20 2021-06-01 中国科学院上海药物研究所 一种tcs-穿膜肽-肿瘤蛋白酶底物肽融合蛋白、其制备方法和用途
EP3628047A1 (en) 2017-05-02 2020-04-01 Sanford Burnham Prebys Medical Discovery Institute Tumor associated monocyte/macrophage binding peptide and methods of use thereof
CN108101966B (zh) * 2017-12-26 2020-10-27 暨南大学 基于细胞穿膜肽的氧化还原敏感多肽及其在疫苗载体中的应用
EP3790534B1 (en) 2018-05-08 2023-08-30 Evonik Operations GmbH Nanoparticle comprising a bio-resorbable polyester, a hydrophilic polymer and an acylated human lactoferrin-derived peptide
CN111499759B (zh) * 2019-01-31 2022-12-20 上海科技大学 一种具有细胞穿膜性的锌指蛋白-乳铁蛋白融合蛋白质及其制备与应用
US12583888B2 (en) 2019-02-04 2026-03-24 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
CN110078834B (zh) * 2019-05-05 2021-07-30 华中科技大学 一种类短肽、辅助透膜剂及其应用
CN112426438B (zh) * 2019-11-14 2023-12-05 上海鑫湾生物科技有限公司 用于调控酸性环境免疫应答的组合物、其制备方法和用途
CN121774830A (zh) * 2020-03-27 2026-04-03 阿拉斯廷护肤品股份有限公司 与色素沉着有关的组合物和方法
CA3246538A1 (en) 2022-03-30 2023-10-05 Evonik Operations Gmbh Formulations composed of cationic lipids and poly(lactic-co-glycolic acid) for the administration of polynucleotides into cells
JP2025535128A (ja) * 2022-10-13 2025-10-22 スティッチング ラドバウド ウニヴェルシテール メディシュ セントルム カーゴ及びインテレクチン１に結合する標的化部分を含む複合体
JP2025540052A (ja) 2022-12-01 2025-12-11 イェール ユニバーシティー 細胞内ペイロード送達用刺激応答性トレースレス操作プラットフォーム

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
JP2818056B2 (ja) 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
JP3207535B2 (ja) * 1992-08-07 2001-09-10 森永乳業株式会社 抗酸化剤
JP3312946B2 (ja) * 1993-03-04 2002-08-12 雪印乳業株式会社 ウイルス感染・増殖抑制剤
DE59708838D1 (de) 1996-08-30 2003-01-09 Jens Peter Fuerste Spiegelselektion und spiegelevolution von nucleinsäuren
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
SE9804614A0 (en) * 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
WO2000004132A1 (en) * 1998-07-15 2000-01-27 Samyang Genex Corporation Mass production method of lactoferrin polypeptide from yeast and useful microorganism thereof
JP3681982B2 (ja) * 1998-07-15 2005-08-10 サムヤン ジェネックス コーポレイション 酵母からラクトフェリンポリペプチドを大量生産する方法及びそれに有用な微生物菌株
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN

Also Published As

Publication number Publication date
ES2361621T3 (es) 2011-06-20
ES2361621T7 (es) 2012-06-14
BRPI0620806A2 (pt) 2011-11-22
EP1966240B1 (en) 2011-03-09
CA2646833A1 (en) 2007-07-12
IL192131A0 (en) 2008-12-29
AU2006332193A1 (en) 2007-07-12
CN101395180B (zh) 2016-06-22
CN101395180A (zh) 2009-03-25
CA2646833C (en) 2019-07-30
KR101317100B1 (ko) 2013-10-15
JP2009521908A (ja) 2009-06-11
ATE501169T1 (de) 2011-03-15
US20130108662A1 (en) 2013-05-02
EP1966240B3 (en) 2011-12-28
AU2006332193B2 (en) 2012-06-28
US20160151504A1 (en) 2016-06-02
JP5264502B2 (ja) 2013-08-14
EP1966240A1 (en) 2008-09-10
PL1966240T3 (pl) 2011-08-31
KR20080091120A (ko) 2008-10-09
MX2008008548A (es) 2008-09-10
IL192131A (en) 2011-10-31
DE602006020617D1 (de) 2011-04-21
US20100061932A1 (en) 2010-03-11
BRPI0620806B1 (pt) 2017-12-05
US9403884B2 (en) 2016-08-02
WO2007076904A1 (en) 2007-07-12
SI1966240T1 (sl) 2011-06-30
PL1966240T6 (pl) 2012-05-31

Similar Documents

Publication Publication Date Title
BRPI0620806B8 (pt) complexo e composição compreendendo um peptídeo e uma molécula carga, e uso da referida composição
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2559062T3 (es) Método para la activación de linfocitos T colaboradores y composición para su uso en el método
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
WO2008057463A3 (en) Peptide-based conditioners
BRPI0511421A (pt) composições cosmética e farmacêutica para tratar materiais contendo queratina, uso de composições cosméticas, molécula efetora que liga queratina, uso da mesma, e, processo
BRPI0606612A2 (pt) expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto
BR0313429A (pt) peptìdeos como excipientes solubilizantes para proteìnas do fator de crescimento beta de transformação
PE20100253A1 (es) Mutantes de fgf21
EA201200515A1 (ru) Полипептиды и их применение
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
BR112022010153A2 (pt) Peptídeos, ácido nucleico, polipeptídeo, composição, complexo bioluminescente, métodos, dipeptídeo, sistema e kit
UY30984A1 (es) Proteinas de fusion de formula m-a para degradar péptidos beta amiloides, composiciones en base a ella, preparacion y aplicaciones.
BR112018003594A2 (pt) cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
BRPI0508670A (pt) proteìnas de buganina modificada, citotoxinas e métodos e usos delas
BR0312521A (pt) Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado
BR0116122A (pt) Peptìdeos e/ou proteìnas bem como seu uso para preparar uma composição farmacêutica, terapêutica e/ou preventiva
WO2005090385A3 (en) Compositions having antimicrobial activity and uses thereof
BRPI0616712B8 (pt) método para amidar polipeptídeos com terminais c de aminoácido básicos por meio de endoproteases específicas
ATE529445T1 (de) Biokinetik zur schnellen beseitigung von polypeptiden
AR075933A1 (es) Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso
BRPI0715331B8 (pt) polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo
BR112022005782A2 (pt) Proteína galectina 9 estabilizada recombinante, vetor recombinante, transformante, composição farmacêutica para prevenção ou tratamento de uma doença óssea, alimento funcional de saúde para prevenção ou melhora de uma doença óssea, e, uso de uma proteína galectina 9 estabilizada recombinante
ES2542227T3 (es) Tratamiento de complicaciones vasculares de diabetes

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/10/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B25A Requested transfer of rights approved
B25D Requested change of name of applicant approved